Prominent PhRMA CEO Departs Amid Shifting Pharmaceutical Lobbying Landscape

The exit of Steve Ubl signals a power shift as the White House takes a more direct approach to drug pricing negotiations.

Apr. 10, 2026 at 6:27pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of polished, geometric objects representing the pharmaceutical industry, such as a glass vial, a pill bottle, and a syringe, arranged elegantly on a clean, monochromatic seamless background. The objects use sharp, dramatic studio lighting and deep shadows to symbolize the abstract concepts of corporate strategy, finance, and the shifting power dynamics within the industry.As the pharmaceutical industry navigates a changing political landscape, the departure of a prominent lobbying figure signals a power shift in how the sector engages with policymakers.Washington Today

The departure of Steve Ubl, the long-time CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), is seen as a reflection of the evolving dynamics between lobbyists, industry executives, and the government. Ubl's exit comes amid a changing political climate where the Trump administration has been bypassing traditional lobbying groups and negotiating drug pricing agreements directly with drugmakers, undercutting the power of industry associations like PhRMA.

Why it matters

Ubl's departure is symbolic of a broader trend in the pharmaceutical industry, where the traditional influence of lobbying groups is being challenged. This shift raises questions about the future of lobbying and the role of industry associations, as companies are increasingly incentivized to engage in direct negotiations with policymakers rather than relying on intermediaries.

The details

During Ubl's tenure, which began in 2015, PhRMA spent a record $38 million on lobbying last year with little to show for it, as the White House has taken a more direct approach to drug pricing negotiations. This has left traditional lobbying groups like PhRMA with diminishing influence. The Trump administration's recent tariff announcement, which exempts drugmakers who dealt directly with the administration, further highlights the shifting power dynamics in the industry.

  • Steve Ubl has been the CEO of PhRMA since 2015.
  • PhRMA spent a record $38 million on lobbying in 2025.

The players

Steve Ubl

The outgoing CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), who has been a significant player in the pharmaceutical lobbying game for years.

Pharmaceutical Research and Manufacturers of America (PhRMA)

A prominent pharmaceutical industry trade group that has traditionally wielded significant influence through lobbying efforts.

Trump administration

The current U.S. presidential administration, which has been taking a more direct approach to drug pricing negotiations, bypassing traditional lobbying groups.

Got photos? Submit your photos here. ›

What’s next

The pharmaceutical industry and lobbying groups will need to adapt their strategies to remain relevant in the changing political landscape, as the White House continues to pursue a more direct approach to drug pricing negotiations.

The takeaway

The exit of a prominent PhRMA CEO signals a power shift in the pharmaceutical industry, where traditional lobbying groups are facing diminishing influence as the White House takes a more direct approach to drug pricing negotiations. This transition highlights the need for industry associations to evolve their strategies to maintain relevance in the changing political climate.